Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Pacira BioSciences, Inc.PCRX · Entity 4928 | Senior Vice President, Finance | October 08, 2026 | October 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Pacira BioSciences, Inc.
Report date October 08, 2026 · Filed October 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 62,284.242 |
Ending reported balance
After 2026-10-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-08 · Exercise / conversion · Acquired 6,000 · Balance 68,284.242 F1: The option exercise and sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on March 12, 2026. Row 2 · 2026-10-08 · Sale · Disposed 6,000 · Balance 62,284.242 F1: The option exercise and sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on March 12, 2026. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.35 · Expires 2026-12-07 | Direct | 0 |
Reported balance
After 2026-10-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-08 · Exercise / conversion · Disposed 6,000 · Balance 0 F1: The option exercise and sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on March 12, 2026. F2: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years. |
Filing footnotes · ownership attribution and instrument terms
F1: The option exercise and sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on March 12, 2026.
F2: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 08, 2026 Filed Oct 9, 2026 23:07 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $32.35 | $0.00 |
DisclosureSEC source: 0001628280-26-065566 · wk-form4_1791587267.xml · derivative · entry 3 RIKER LAUREN · CIK 0001545439 · Senior Vice President, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2026-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The option exercise and sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on March 12, 2026. F2 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years. F1 · derivative.underlying_shares: The option exercise and sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on March 12, 2026. Read SEC document |
| October 08, 2026 Filed Oct 9, 2026 23:07 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 6,000 | $36.32 | $217,920.00 |
DisclosureSEC source: 0001628280-26-065566 · wk-form4_1791587267.xml · nonDerivative · entry 2 RIKER LAUREN · CIK 0001545439 · Senior Vice President, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,284.242 F1 · shares: The option exercise and sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on March 12, 2026. Read SEC document |
| October 08, 2026 Filed Oct 9, 2026 23:07 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 6,000 | $32.35 | $194,100.00 |
DisclosureSEC source: 0001628280-26-065566 · wk-form4_1791587267.xml · nonDerivative · entry 1 RIKER LAUREN · CIK 0001545439 · Senior Vice President, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,284.242 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The option exercise and sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on March 12, 2026. Read SEC document |
| June 11, 2026 Filed Jun 13, 2026 01:07 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 6,115 | $23.50 | $143,702.50 |
DisclosureSEC source: 0001628280-26-043009 · wk-form4_1781312864.xml · nonDerivative · entry 1 RIKER LAUREN · CIK 0001545439 · Senior Vice President, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,284.242 F1 · shares: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on March 12, 2026. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 21:57 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Tax withholdingCommon Stock | 3,187 | $22.32 | $71,133.84 |
DisclosureSEC source: 0001628280-26-041332 · wk-form4_1780696632.xml · nonDerivative · entry 1 RIKER LAUREN · CIK 0001545439 · Senior Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,399.242 F1 · shares: Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:02 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 19,273 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-008076 · wk-form4_1771016519.xml · nonDerivative · entry 1 RIKER LAUREN · CIK 0001545439 · Senior Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,586.242 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on February 15, 2027, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 23:24 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 4,000 | $20.81 | $83,240.00 |
DisclosureSEC source: 0001628280-26-005158 · wk-form4_1770161045.xml · nonDerivative · entry 2 RIKER LAUREN · CIK 0001545439 · Senior Vice President, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,313.242 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.35 to $21.28, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 3. Read SEC document |
| January 30, 2026 Filed Feb 3, 2026 23:24 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Tax withholdingCommon Stock | 2,751 | $20.54 | $56,505.54 |
DisclosureSEC source: 0001628280-26-005158 · wk-form4_1770161045.xml · nonDerivative · entry 1 RIKER LAUREN · CIK 0001545439 · Senior Vice President, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,313.242 F1 · shares: Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 22:30 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 1,416 | $24.24 | $34,323.84 |
DisclosureSEC source: 0001628280-26-000967 · wk-form4_1767738641.xml · nonDerivative · entry 2 RIKER LAUREN · CIK 0001545439 · Senior Vice President, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,064.242 F3 · shares: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:30 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Tax withholdingCommon Stock | 159 | $24.46 | $3,889.14 |
DisclosureSEC source: 0001628280-26-000967 · wk-form4_1767738641.xml · nonDerivative · entry 1 RIKER LAUREN · CIK 0001545439 · Senior Vice President, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,480.242 F1 · shares: Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award. F2 · balance_after: Includes 1,075.242 shares of common stock acquired under the issuer's employee stock purchase plan in December 2025. Read SEC document |
| June 04, 2025 Filed Jun 5, 2025 21:40 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 5,578.335 | $26.21 | $146,208.16 |
DisclosureSEC source: 0001396814-25-000069 · wk-form4_1749159397.xml · nonDerivative · entry 2 RIKER LAUREN · CIK 0001545439 · Senior Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,564 F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.15 to $26.38, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 21:40 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Tax withholdingCommon Stock | 3,374 | $26.40 | $89,073.60 |
DisclosureSEC source: 0001396814-25-000069 · wk-form4_1749159397.xml · nonDerivative · entry 1 RIKER LAUREN · CIK 0001545439 · Senior Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,142.335 F1 · kind: Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 23:25 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 30,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001396814-25-000029 · wk-form4_1738711516.xml · nonDerivative · entry 1 RIKER LAUREN · CIK 0001545439 · Senior Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,516.335 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on February 1, 2026, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 23:22 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Tax withholdingCommon Stock | 159 | $18.33 | $2,914.47 |
DisclosureSEC source: 0001396814-25-000005 · wk-form4_1736205763.xml · nonDerivative · entry 1 RIKER LAUREN · CIK 0001545439 · Senior Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,916.335 F1 · kind: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. Read SEC document |
| June 12, 2024 Filed Jun 13, 2024 22:15 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 3,970 | $28.72 | $114,018.40 |
DisclosureSEC source: 0001396814-24-000085 · wk-form4_1718316907.xml · nonDerivative · entry 2 RIKER LAUREN · CIK 0001545439 · Senior Vice President, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,075.335 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.33 to $29.32, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 3. Read SEC document |
| June 12, 2024 Filed Jun 13, 2024 22:15 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 21,360 | $0.00 | $0.00 |
DisclosureSEC source: 0001396814-24-000085 · wk-form4_1718316907.xml · nonDerivative · entry 1 RIKER LAUREN · CIK 0001545439 · Senior Vice President, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,045.335 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2025, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 21:10 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Tax withholdingCommon Stock | 1,843 | $30.89 | $56,930.27 |
DisclosureSEC source: 0001396814-24-000055 · wk-form4_1717621792.xml · nonDerivative · entry 1 RIKER LAUREN · CIK 0001545439 · Senior Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,685.335 F1 · kind: Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 22:25 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Tax withholdingCommon Stock | 159 | $32.00 | $5,088.00 |
DisclosureSEC source: 0001396814-24-000014 · wk-form4_1704407150.xml · nonDerivative · entry 1 RIKER LAUREN · CIK 0001545439 · Senior Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,528.335 F1 · kind: Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award. Read SEC document |
| July 05, 2023 Filed Jul 8, 2023 00:04 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 643 | $38.91 | $25,019.13 |
DisclosureSEC source: 0001209191-23-041865 · doc4.xml · nonDerivative · entry 1 Riker Lauren Bullaro · CIK 0001545439 · Senior Vice President, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,687.335 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.67 to $39.40, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: Includes 643.335 shares of common stock acquired under the issuer's employee stock purchase plan in June 2023. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:39 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $38.74 | $0.00 |
DisclosureSEC source: 0001209191-23-038030 · doc4.xml · derivative · entry 5 Riker Lauren Bullaro · CIK 0001545439 · Senior Vice President, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-06-14 F6 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:39 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 7 | $39.01 | $273.07 |
DisclosureSEC source: 0001209191-23-038030 · doc4.xml · nonDerivative · entry 4 Riker Lauren Bullaro · CIK 0001545439 · Senior Vice President, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,687 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.000 to $39.010, inclusive. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:39 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 5,773 | $38.52 | $222,375.96 |
DisclosureSEC source: 0001209191-23-038030 · doc4.xml · nonDerivative · entry 3 Riker Lauren Bullaro · CIK 0001545439 · Senior Vice President, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,694 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.000 to $38.995, inclusive. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:39 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 586 | $37.47 | $21,957.42 |
DisclosureSEC source: 0001209191-23-038030 · doc4.xml · nonDerivative · entry 2 Riker Lauren Bullaro · CIK 0001545439 · Senior Vice President, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,467 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.975 to $37.965, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 3 through 5. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:39 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-038030 · doc4.xml · nonDerivative · entry 1 Riker Lauren Bullaro · CIK 0001545439 · Senior Vice President, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,053 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2024, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 01:31 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 616 | $37.87 | $23,324.84 |
DisclosureSEC source: 0001209191-23-035262 · doc4.xml · nonDerivative · entry 2 Riker Lauren Bullaro · CIK 0001545439 · Senior Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,053 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 01:31 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 591 | $38.99 | $23,043.68 |
DisclosureSEC source: 0001209191-23-035262 · doc4.xml · nonDerivative · entry 1 Riker Lauren Bullaro · CIK 0001545439 · Senior Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,669 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. F2 · balance_after: Includes 408 shares of common stock acquired under the issuer's employee stock purchase plan in June 2022. Read SEC document |
| June 08, 2022 Filed Jun 8, 2022 23:44 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 14,600 | $0.00 Strike: $59.39 | $0.00 |
DisclosureSEC source: 0001209191-22-035231 · doc4.xml · derivative · entry 3 Riker Lauren Bullaro · CIK 0001545439 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,600 Underlying: Common Stock · 14,600 shares Expires 2032-06-08 F3 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| June 08, 2022 Filed Jun 8, 2022 23:44 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 5,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-035231 · doc4.xml · nonDerivative · entry 2 Riker Lauren Bullaro · CIK 0001545439 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,852 F2 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2023, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 23:44 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 1,150 | $61.37 | $70,580.10 |
DisclosureSEC source: 0001209191-22-035231 · doc4.xml · nonDerivative · entry 1 Riker Lauren Bullaro · CIK 0001545439 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,002 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 21:00 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,300 | $0.00 Strike: $10.81 | $0.00 |
DisclosureSEC source: 0001209191-22-018518 · doc4.xml · derivative · entry 4 Riker Lauren Bullaro · CIK 0001545439 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,300 shares Expires 2022-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested and became exercisable as to 25% of the option shares on June 5, 2013 and vested as to the remaining shares in successive equal monthly installments for the subsequent 36 months. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 21:00 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 900 | $71.95 | $64,755.00 |
DisclosureSEC source: 0001209191-22-018518 · doc4.xml · nonDerivative · entry 3 Riker Lauren Bullaro · CIK 0001545439 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,152 F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.895 to $72.005, inclusive. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 21:00 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 8,400 | $71.14 | $597,576.00 |
DisclosureSEC source: 0001209191-22-018518 · doc4.xml · nonDerivative · entry 2 Riker Lauren Bullaro · CIK 0001545439 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,052 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.84 to $71.74, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 1 and 2. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 21:00 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 9,300 | $10.81 | $100,533.00 |
DisclosureSEC source: 0001209191-22-018518 · doc4.xml · nonDerivative · entry 1 Riker Lauren Bullaro · CIK 0001545439 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,452 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 18, 2022 Filed Jan 21, 2022 00:22 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $10.81 | $0.00 |
DisclosureSEC source: 0001209191-22-004200 · doc4.xml · derivative · entry 3 Riker Lauren Bullaro · CIK 0001545439 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,300 Underlying: Common Stock · 2,500 shares Expires 2022-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested and became exercisable as to 25% of the option shares on June 5, 2013 and vested as to the remaining shares in successive equal monthly installments for the subsequent 36 months. Read SEC document |
| January 18, 2022 Filed Jan 21, 2022 00:22 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 2,500 | $64.97 | $162,430.00 |
DisclosureSEC source: 0001209191-22-004200 · doc4.xml · nonDerivative · entry 2 Riker Lauren Bullaro · CIK 0001545439 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,152 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| January 18, 2022 Filed Jan 21, 2022 00:22 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 2,500 | $10.81 | $27,025.00 |
DisclosureSEC source: 0001209191-22-004200 · doc4.xml · nonDerivative · entry 1 Riker Lauren Bullaro · CIK 0001545439 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,652 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| January 04, 2022 Filed Jan 10, 2022 22:32 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $61.60 | $0.00 |
DisclosureSEC source: 0001209191-22-002726 · doc4.xml · derivative · entry 2 Riker Lauren Bullaro · CIK 0001545439 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2032-01-04 F2 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on December 7, 2022, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| January 04, 2022 Filed Jan 10, 2022 22:32 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-002726 · doc4.xml · nonDerivative · entry 1 Riker Lauren Bullaro · CIK 0001545439 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,152 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on January 2, 2023, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| July 29, 2021 Filed Jul 30, 2021 20:21 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 90 | $0.00 Strike: $10.81 | $0.00 |
DisclosureSEC source: 0001209191-21-048784 · doc4.xml · derivative · entry 6 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,800 Underlying: Common Stock · 90 shares Expires 2022-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested and became exercisable as to 25% of the option shares on June 5, 2013 and vested as to the remaining shares in successive equal monthly installments for the subsequent 36 months. Read SEC document |
| July 29, 2021 Filed Jul 30, 2021 20:21 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 90 | $60.81 | $5,472.90 |
DisclosureSEC source: 0001209191-21-048784 · doc4.xml · nonDerivative · entry 4 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,152 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| July 29, 2021 Filed Jul 30, 2021 20:21 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 90 | $10.81 | $972.90 |
DisclosureSEC source: 0001209191-21-048784 · doc4.xml · nonDerivative · entry 3 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,242 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| July 28, 2021 Filed Jul 30, 2021 20:21 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,410 | $0.00 Strike: $10.81 | $0.00 |
DisclosureSEC source: 0001209191-21-048784 · doc4.xml · derivative · entry 5 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,890 Underlying: Common Stock · 2,410 shares Expires 2022-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested and became exercisable as to 25% of the option shares on June 5, 2013 and vested as to the remaining shares in successive equal monthly installments for the subsequent 36 months. Read SEC document |
| July 28, 2021 Filed Jul 30, 2021 20:21 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 2,410 | $60.85 | $146,648.50 |
DisclosureSEC source: 0001209191-21-048784 · doc4.xml · nonDerivative · entry 2 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,152 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.81 to $60.858, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 28, 2021 Filed Jul 30, 2021 20:21 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 2,410 | $10.81 | $26,052.10 |
DisclosureSEC source: 0001209191-21-048784 · doc4.xml · nonDerivative · entry 1 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,562 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · balance_after: Includes 421 shares of common stock acquired under the issuer's employee stock purchase plan in June 2021. Read SEC document |
| June 11, 2021 Filed Jun 12, 2021 00:39 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 2,003 | $59.85 | $119,879.55 |
DisclosureSEC source: 0001209191-21-040092 · doc4.xml · nonDerivative · entry 2 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,731 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.820 to $59.845, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth this footnote. Read SEC document |
| June 09, 2021 Filed Jun 12, 2021 00:39 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $60.96 | $0.00 |
DisclosureSEC source: 0001209191-21-040092 · doc4.xml · derivative · entry 3 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2031-06-09 F3 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| June 09, 2021 Filed Jun 12, 2021 00:39 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 2,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-040092 · doc4.xml · nonDerivative · entry 1 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,734 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2022, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 20:17 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 1,047 | $61.04 | $63,905.74 |
DisclosureSEC source: 0001209191-21-038894 · doc4.xml · nonDerivative · entry 1 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,134 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. Read SEC document |
| March 17, 2021 Filed Mar 18, 2021 00:03 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $10.81 | $0.00 |
DisclosureSEC source: 0001209191-21-021585 · doc4.xml · derivative · entry 6 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,300 Underlying: Common Stock · 2,000 shares Expires 2022-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested and became exercisable as to 25% of the option shares on June 5, 2013 and vested as to the remaining shares in successive equal monthly installments for the subsequent 36 months. Read SEC document |
| March 17, 2021 Filed Mar 18, 2021 00:03 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 2,000 | $70.01 | $140,020.00 |
DisclosureSEC source: 0001209191-21-021585 · doc4.xml · nonDerivative · entry 4 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,181 F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.00 to $70.04, inclusive. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.